Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-Term Pre-Eclampsia Cases

Published: Thursday, July 12, 2012
Last Updated: Tuesday, July 17, 2012
Bookmark and Share
The test correctly identifies 80% of women at risk for the development of pre-term pre-eclampsia according to a study in collaboration with the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium.

Pronota NV announces that it has successfully validated its mid-gestation pre-eclampsia screening test.

Pre-eclampsia is responsible for 50,000 maternal deaths annually and is a major cause of premature and still births. This potentially devastating condition is unique to pregnancy and primarily affects women who are pregnant for the first time. Between 4 and 7% of healthy women have their first pregnancy complicated with pre-eclampsia with no prior predisposition or warning signs. Pronota’s assay, which combines five protein biomarkers and blood pressure, offers an improvement to existing tests.

Dr. Philip Baker, Professor of Obstetrics and Gynaecology at the University of Alberta, commented: “A test that correctly identifies women at risk of pre-eclampsia could allow physicians to adapt prenatal care and lead to improved outcomes for both mothers and infants.”

Pronota used its proprietary proteomics platforms to identify, verify and validate a panel of novel blood biomarkers which are predictive of pre-eclampsia at the mid-gestation time point. An unbiased large scale proteomics biomarker discovery experiment was followed by verification of the results in 300 women who either subsequently developed pre-eclampsia or did not. The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed pre-eclampsia that resulted in birth of a premature baby (preterm pre-eclampsia). These MS based results were successfully translated to an ELISA type read out. This important milestone was achieved through a longstanding scientific collaboration with Professor Baker from the University of Alberta, Professor North from King’s College, London and Dr. Myers from Manchester Maternal & Fetal Health Research Centre, UK.

Professor North from King’s College, London, commented: “The prediction model developed in this study represents a rare example of a rigorously validated proteomic biomarker study, the findings of which have the potential to be translated into a clinical prediction tool.”

The cohort used for the study was compiled by the SCOPE Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centres across Australia, New Zealand, the UK and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.

Dr. Jenny Myers, Clinical Senior Lecturer, Manchester Maternal & Fetal Health Research Centre, UK, will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva in July.

Katleen Verleysen, CEO of Pronota, said: “We are very pleased to bring forward a novel combination of biomarkers predictive for pre-eclampsia, which will provide physicians with the best tools to ensure the highest quality of care for patients. This study also validates Pronota’s approach towards biomarker discovery and validation, a company capable of taking unbiased discovery results through to validation.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pronota is to Receive Patent on Biomarker for Diagnosing Renal Failure
USPTO has allowed Company’s patent for the use of a blood-based biomarker LG3.
Friday, June 07, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos